Efficacy and safety results from AvaALL: an open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo)
Keyword(s):
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS8578-TPS8578
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(36)
◽
pp. 5240-5246
◽
Keyword(s):
2007 ◽
Vol 2
(8)
◽
pp. S693-S694
Keyword(s):
2019 ◽
Vol 105
(1)
◽
pp. E496-E497
Keyword(s):